Deals In Depth: January 2013
Executive Summary
Gilead licensed rights to four preclinical antibodies from MacroGenics. Stryker bought Chinese device company Trauson for $751 million. Biopharma companies raised double the amount from December, bringing in $2.8 billion, while device funding dropped to $269 million.